Navigation Links
Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
Date:8/4/2008

74 percent of patients achieved SVR 12 with 48-week boceprevir-based

combination therapy

High SVR 24 rate also reported for 28-week boceprevir arm

KENILWORTH, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported top-line results from a planned interim analysis of a Phase II study of boceprevir, its investigational oral hepatitis C protease inhibitor. The analysis showed a high rate of sustained virologic response (SVR) in patients receiving boceprevir-based combination therapy in this study of 595 treatment-nave patients with chronic hepatitis C virus (HCV) genotype 1.

In a 48-week treatment regimen, the SVR rate at 12 weeks after the end of treatment (SVR 12) was 74 percent (ITT) in patients who received 4 weeks of PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) prior to the addition of boceprevir (800 mg TID) (P/R lead-in), compared to 38 percent for patients in the control group receiving 48-weeks of PEGINTRON and REBETOL alone.(1-3)

Patients in the study who received 48-weeks of boceprevir in combination with PEGINTRON and REBETOL from the beginning of treatment (no P/R lead-in) achieved 66 percent SVR 12.

In the two 28-week boceprevir arms of the study, SVR at 24 weeks after the end of treatment (SVR 24) was 56 percent and 55 percent for patients in the lead-in and no lead-in arms, respectively.

Importantly, for patients who received the PEGINTRON and REBETOL lead in and had rapid virologic response (RVR), defined as undetectable virus (HCV-RNA) in plasma after 4 weeks of boceprevir treatment, SVR (ITT) was 82 percent in the 28-week regimen and 92 percent in the 48 week regimen.

"These top-l
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
2. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
3. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
4. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
5. Inspires Phase 3 CF Trial, Using PARIs Nebulizer & Compressor, Shows Positive Top-Line Results
6. Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery
7. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
8. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
9. Schering-Plough Reports Top-Line Results of the IDEAL Study
10. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
11. Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, ... OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE ... JURISDICTION AbbVie (NYSE: ABBV ) today announced financial ... "This was another very strong quarter for AbbVie, ... original guidance and announced plans to merge with Shire, a ...
(Date:7/25/2014)... N.Y. , July 25, 2014 /PRNewswire-iReach/ -- Dr. ... clinic, GPM Pediatrics, reacts to a recent study, which ... Photo - http://photos.prnewswire.com/prnh/20140723/129709 ... exposed to severe stress are more likely than others to ... months before pregnancy." There were two specific types ...
(Date:7/24/2014)... July 24, 2014  Parnell Pharmaceuticals Holdings Ltd ... will be added to Parnell,s already extensive pipeline ... Ltd, a biotechnology company. The compounds now known ... promise in bone regeneration and dermal regeneration, respectively. ... compounds for the veterinary market with the potential ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
... Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that ... 2012 at 8:30 a.m. Eastern Time to provide an update ... Inc., a member of the Roche Group (SIX: RO, ROG; ... (888) 660-6127 International Dial-in Number: (973) 890-8355 Participant Code:  40392582 ...
... SINGAPORE, Dec. 30, 2011 /PRNewswire-Asia/ -- Biosensors International Group, ... SGX: B20), a developer, manufacturer and marketer of innovative ... today announced it will be participating in the 30th ... from 9th to 12th January 2012 in San Francisco, ...
Cached Medicine Technology:Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation 2Biosensors International to Participate in the 30th Annual J.P. Morgan Healthcare Conference 2
(Date:7/25/2014)... July 25, 2014 Eye & Vision ... at their office location by expanding a new specialized ... kind comprehensive visual electro-physiology clinic. , By acquiring specialized ... of experience in vision problems, patients with vision loss ... take advantage of the implementation of this specialized vision ...
(Date:7/25/2014)... 2014 The European liquid chromatography reagents ... with analysis and forecast of revenue. The liquid chromatography ... million in 2013, and is estimated to grow to ... 9.4 %, from 2013 to 2018. , Browse through ... to get an idea of the in-depth analysis provided. ...
(Date:7/25/2014)... genes may play a greater role in language delay ... Researchers found more evidence that language traits, such ... inherited. The study involving 473 sets of twins ... language performance for twins than single-born children) was greater ... disputes hypotheses that attribute delays in early language acquisition ...
(Date:7/25/2014)... are switched on or off plays a key role ... UT Southwestern Medical Center researchers have found., The research ... and diabetes, since the transcription factor involved spliced ... the body,s sensitivity to insulin and leptin signaling. Insulin ... of food intake and sugar disposal, and obesity and ...
(Date:7/25/2014)... The American Brain Tumor Association (ABTA) announced today ... Distinguished Events, and Corporate and Special Events Manager - ... be joining the ABTA in the newly created position ... roll out of a nationwide brain tumor volunteer effort ... volunteer network will provide the Chicago-based ABTA with a ...
Breaking Medicine News(10 mins):Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 2Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Genes May Be Key to Language Delay in Kids 2Health News:Manipulating key protein in the brain holds potential against obesity and diabetes 2Health News:American Brain Tumor Association Recruits Director to Lead New Volunteer Network 2
... and efficacy of first FDA-approved nebulized ... COPD -, NAPA, Calif., May 16 Dey, ... given at the International,Conference of the American Thoracic Society ... Center. One of the presentations details the,effects on dyspnea ...
... mastectomy (total breast removal) for early-stage breast cancer has ... in Rochester. The increase follows a steady decline during ... for this increase are unclear. But they have determined ... resonance imaging (MRI) prior to surgery to treat early-stage ...
... sooner if therapy is working , , FRIDAY, May 16 ... levels of circulating tumor cells can help doctors more ... with metastatic breast cancer, according to a Georgetown University ... weeks, and sometimes months, to determine if a particular ...
... /Xinhua-PRNewswire-FirstCall/ --,Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ... distributor,of high-quality, pharmaceutical grade glucose products in China, ... March 31, 2008., Third Quarter of ... to $20.7 million -- Gross profit rose ...
... May 16 IDM Pharma, Inc.,(Nasdaq: IDMI ... Company,s lead product candidates will be made at ... annual meeting. Data presented,at the meeting will support ... L-MTP-PE, as well as patients with non-small lung,cancer ...
... wake of divorce, illness, violence and other problems that ... experience temporary separations from one or both parents before ... May/June issue of Ambulatory Pediatrics, a new, community-wide study ... at increased risk for learning difficulties and that these ...
Cached Medicine News:Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 2Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 3Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 4Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 5Health News: Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers 2Health News: Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers 3Health News:Blood Test Helps Docs Assess Breast Cancer Treatment 2Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 2Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 3Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 4Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 5Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 6Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 7Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 8Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 9Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 10Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 11Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 12Health News:IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting 2Health News:IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting 3Health News:Separation from mom, dad linked with learning trouble in kids 2Health News:Separation from mom, dad linked with learning trouble in kids 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: